AI-driven drug discovery has gotten much of the glory in pharma.
Isomorphic Labs — which is leveraging an AI drug discovery platform based on Nobel Prize-winning AlphaFold software — pulled in the largest biotech investment haul this year to date with a $600 million fundraising round in March.
And drug discovery is a prime focus for many of the highest valued AI companies working in pharma. Tempus AI, which has a market cap of about $9 billion, got its start leveraging molecular data for precision cancer care and has since expanded its capabilities to include drug discovery. Its services have been used by almost all of pharma’s largest public companies.
So far, none of this momentum has resulted in a new drug approval.
Insilico Medicine is one of the frontrunners in that race with a candidate it calls the “first…